Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced the termination of its agreement with DePuy Synthes for co-promotion of EXPAREL, effective January 2, 2021. This collaboration, which started in January 2017, enhanced EXPAREL's usage in orthopedic surgical settings. Pacira expressed gratitude for the partnership, emphasizing the significance of EXPAREL in opioid-sparing protocols. Following the termination, Pacira plans to manage EXPAREL independently and anticipates improved economics. The company is also building a training center in Tampa for better customer education and support.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 10:00 AM ET. Interested investors can access the live audio through the company’s website, with a replay available for two weeks post-event. Pacira specializes in non-opioid pain management and regenerative health solutions, with its flagship product, EXPAREL®, a long-acting analgesic launched in April 2012. The company aims to reduce opioid reliance and recently acquired the iovera⁰ system for targeted nerve pain management.
PARSIPPANY, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 Jefferies Virtual Healthcare Conference on June 3, 2020, at 9:30 AM ET. Interested parties can access the live audio via the company's Events page. A replay will be available for two weeks post-event.
Pacira is known for its non-opioid pain management solutions, including EXPAREL®, a long-acting local analgesic launched in April 2012, and the iovera⁰ system, acquired in April 2019.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 20, 2020, at 9:45 AM ET. Interested parties can access a live audio stream on the company's website, with a replay available for two weeks post-event. Pacira is dedicated to non-opioid pain management technologies, including its long-acting local analgesic EXPAREL®, which launched in 2012. The company also acquired the iovera⁰ cryoanalgesia device in April 2019, aiming to enhance pain management and reduce opioid reliance.
Pacira BioSciences (PCRX) reported a 16% revenue increase for Q1 2020, totaling $105.7 million, driven by a 12% rise in EXPAREL sales to $101.3 million. GAAP net income stood at $8.2 million ($0.19/share), a recovery from a net loss of $2.8 million in Q1 2019. Despite early growth, the company has withdrawn full-year guidance due to COVID-19 uncertainties, although it anticipates some mitigation from expense reductions. Cash reserves are strong at $353.6 million, positioning the company for future recovery as elective surgeries resume.
Summary not available.
Summary not available.